Key result
No prior statin therapy in OCAD with LDL-C <1.8 mmol/L linked to ~109% higher mortality.
Why the study?
The study investigated the effect of prior statin therapy on cardiovascular outcomes in patients diagnosed with obstructive coronary artery disease and low-density lipoprotein cholesterol <1.8 mmol/L.
Does prior statin therapy reduce MACCE and mortality in patients with an initial diagnosis of OCAD and LDL-C <1.8 mmol/L compared to those with naturally low LDL-C?
Cohort (n=1,330)
Does prior statin therapy reduce MACCE and mortality in patients with an initial diagnosis of OCAD and LDL-C <1.8 mmol/L compared to those with naturally low LDL-C?
In patients with newly diagnosed obstructive CAD and LDL-C <1.8 mmol/L, achieving this low LDL-C via prior statin therapy is associated with significantly lower all-cause and cardiovascular mortality compared to having naturally low LDL-C without statins.
Answers are grounded in this paper and cite their sources.
Prior statin use linked to lower mortality in low-LDL OCAD; leaves open whether therapy modifies risk beyond LDL and requires RCTs.
This study investigated the effect of prior statin therapy on cardiovascular outcomes in patients with a diagnosis of obstructive coronary artery disease (OCAD) and low-density lipoprotein cholesterol (LDL-C) <1.8 mmol/L. A total of 1330 patients with baseline LDL-C <1.8 mmol/L were included; 548 had received prior statin therapy [prior statin (+)] and 782 had no prior statin [prior statin (−)]. Major adverse cardiac and cerebral event (MACCE) during hospitalization and a median follow-up of 25 months were analyzed. Compared with the prior statin (−) group, who displayed similar atherosclerotic cardiovascular disease risk burden including 71.6% with hypertension, 39.1% with diabetes, and 76.1% with ≥3 risk factors, the prior statin (+) group had significantly lower incidence of composite MACCE, all-cause death and cardiovascular death. After multivariable adjustment, non-prior statin therapy was independently associated with all-cause death [hazard ratio (HR) 2.09, 95% confidence interval (CI), 1.13-3.87, P = .019] and cardiovascular death (HR 2.28, 95% CI, 1.04-5.00, P = .040), particularly in the subgroups aged ≥65 years and with hypertension. Overall, compared with "naturally" LDL-C <1.8 mmol/L without statin, prior statin therapy to achieve an LDL-C <1.8 mmol/L independently predicted a lower risk of all-cause and cardiovascular mortality in patients with a diagnosis of OCAD.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) conducted a cohort in Obstructive coronary artery disease (OCAD) with LDL-C <1.8 mmol/L (n=1,330). Prior statin therapy vs. No prior statin therapy was evaluated on All-cause death (risk associated with non-prior statin therapy) (HR 2.09, 95% CI 1.13-3.87, p=0.019). Non-prior statin therapy in patients with OCAD and baseline LDL-C <1.8 mmol/L was independently associated with an increased risk of all-cause death.
Synapse has enriched 10 related papers. Consider them for comparative context: